Admission Pentraxin-3 Level Predicts Severity of Community-Acquired Pneumonia Independently of Etiology.
Proteomics Clin Appl. 2018 Dec 17;:e1800117
Authors: Luo Q, He X, Ning P, Zheng Y, Yang D, Xu Y, Shang Y, Gao Z
PURPOSE: Timely and accurate triaging of patients with community-acquired pneumonia (CAP) is difficult for clinicians. Pentraxin-3 (PTX3) is a non-specific marker of disease severity; however, PTX3 data from CAP patients are lacking.
EXPERIMENTAL DESIGN: An observational, prospective study of CAP patients was conducted in 2016. Plasma PTX3 levels were determined with quantitative ELISA. The primary endpoint was diagnosis of severe CAP (SCAP); the secondary endpoint was hospital mortality or discharge from the hospital.
RESULTS: Among 188 enrolled patients, 88 were diagnosed with SCAP, and 17 died during the hospital stay. Admission PTX3 levels were higher in patients with high CURB-65 or PSI scores (p < 0.0001 for both), and were unaffected by etiology. PTX3 demonstrated good performance in predicting both SCAP in CAP patients (AUC = 0.847) and 30-day mortality of CAP patients (AUC = 0.796). PTX3 combined with CURB-65 improved prediction performance (p = 0.0379). Furthermore, multivariate Cox regression analysis confirmed ≥33.52 ng/mL PTX3 as an independent predictor of 30-day survival.
CONCLUSIONS AND CLINICAL RELEVANCE: Admission levels of PTX3 were useful for predicting severity of CAP, independent of possible pathogens. PTX3 can improve prognostic accuracy of severity scores. Detection of PTX3 on admission might be useful for clinical judgement.
TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT03093220, Date of registration: March 28, 2017 (retrospectively registered) This article is protected by copyright. All rights reserved.
PMID: 30557448 [PubMed - as supplied by publisher]